Session Details

Plenary Session 4 - Emerging Engineering Strategies in Regenerative Medicine
Sunday, September 15, 2019 08:45 AM - 10:15 AM 
Plenary Hall
Strategies to regenerate human tissues must unlock the potential of regenerative cells, both inside and outside the body. This session will highlight creative new approaches to promote tissue regeneration, including therapeutic cell delivery, therapeutic tissue engineering, and endogenous tissue regeneration. These new approaches, and combinations thereof, may represent the future of safe and effective medical treatments.

Chair: William Murphy, PhD, University of Wisconsin Madison, USA


Engineering autologous therapies for regenerative medicine
William Murphy, PhD, University of Wisconsin, USA
Despite their high regenerative potential, musculoskeletal tissues cannot heal spontaneously if the defects have critically large size. This is a significant clinical problem, as there are millions of grafting procedures performed worldwide every year. Transplantation of autologous or allogeneic tissues has been limited by supply and safety concerns, and synthetic alternatives to transplantation still show inferior performance. Our recent studies combine two emerging regenerative strategies that hold broad promise for clinical regenerative medicine: i) the use of patient derived cells and tissues, and ii) activation of patient-derived tissues with therapeutic mRNA. Our approach has involved delivering mRNA to autologous cells and thereby “engineering” the tissue regeneration process. The fundamentals of this approach could provide a path toward clinical translation, as the effectors of tissue regeneration are patient-derived, and the mRNA biologics are transient and traceless. This talk will describe our recent progress using mRNA delivery in the context of skin wound healing, skeletal tissue regeneration, and spinal cord regeneration.

Harnessing hPSC-derived Cardiac Progenitor Cells and Cardiac Fibroblasts for Myocardial Repair
Timothy Kamp, MD, PhD, Stem Cell and Regenerative Medicine Center, UW-Madison, USA
Heart failure is a growing clinical problem which continues to confer a poor prognosis despite advances in pharmacological therapies. Strategies to remuscularize the failing myocardium with cell-based therapies have met with limited success, but new cell preparations and approaches using human pluripotent stem cell (hPSC) derivatives open promising new avenues for regeneration of the failing heart. The presentation will describe advances in generating populations of hPSC-derived cardiac fibroblasts and cardiac progenitor cells. Applications using these novel cell populations for tissue engineering and cell-based strategies for cardiac repair will be presented.

Identifying endothelial stem cells for vascular regeneration
Mervin Yoder, MA, MD, Indiana University School of Medicine, USA
The cellular mechanisms responsible for endothelial repair and regeneration remain poorly understood. Emerging evidence implicates resident vascular endothelial stem and progenitor cells (RVESP) as the principle elements critical for endothelial replacement and regeneration. We have identified enrichment for RVESP in murine and human blood vessels using selection for cells expressing an ATP binding cassette transporter. Cell fate mapping of vascular endothelial progeny derived from RVESP, as well as, clonal in vitro colony assays and prospective isolation and single cell transplantation studies in primary and secondary recipient mice have clarified the identity of the cells as RVESP. These cells may serve as a cell therapy for patients with vascular diseases.

Wiliam Murphy PhD
University of Wisconsin

Timothy Kamp MD, PhD
Stem Cell and Regenerative Medicine Center, UW-Madison

Wiliam Murphy PhD
University of Wisconsin

Mervin Yoder MD
Director Emeritus
Indiana University School of Medicine